Last week, we had the pleasure of welcoming students from the Barcelona International Youth Science Challenge (BIYSC) to #iVascular! 🌟 These future professionals were excited to see firsthand how our medical devices are created and the impact they have on patient care. Their enthusiasm and curiosity remind us why we do what we do. #MedicalInnovation #BIYSC
Info
The purpose of iVascular is to develop innovative advanced medical devices and therapies for the treatment of disorders of the cardiovascular system. Its staff has extensive knowledge of biopolymers, coatings, drug delivery, mechanical engineering, medicine and pharmacy. They bring together recognised experience in the development of medical devices and implants. Thanks to the know-how provided by our scientists and technicians and an appropriate investment in technology, iVascular has implemented a vertical integration project allowing it to develop, innovate and produce cardiovascular devices from basic raw materials (plastics, polymers, metals, etc.) to the final device or implant. iVascular possesses and develops its own technologies, which have made possible the vertical integration of each and every one of the processes involved in developing a device, from the earliest design stages through to final production. In this way we guarantee the highest quality standards in all our products. iVascular has a technology center with more than 1000 m² of clean rooms (ISO 7 and ISO 8) and 250 m² of R&D laboratories equipped with the most comprehensive, advanced instrumentation in the biotechnology field. Through its direct and indirect sales network, iVascular is present in more than 70 countries around the world, and is providing with full range of products for interventional cardiology and endovascular procedures. For more information about iVascular, please, visit www.ivascular.global or If you have any questions or comments, we are ready to help you out by an e-mail to info@ivascular.global
- Website
-
http://www.ivascular.global
Externer Link zu iVascular
- Branche
- Herstellung medizinischer Geräte
- Größe
- 201–500 Beschäftigte
- Hauptsitz
- Freiburg im Breisgau
- Art
- Personengesellschaft (OHG, KG, GbR etc.)
- Gegründet
- 2010
- Spezialgebiete
- Medical Devices, Polymer Science, Drug Delivery, Cardiovascular devices, Endovascular, Interventional Cardiology, Drug Eluting Stent und Drug Coated Balloon
Orte
Beschäftigte von iVascular
Updates
-
LUMIFollow evaluates Luminor for femoropopliteal lesions in over 500 patients at 12 and 24 months, in real-world practice. The registry shows a low fTLR of 94.7% at 1 year. Real-world data continues to confirm the clinical safety and long-term efficacy of DCBs in fempop lesions. #iVascular #LuminorDCB #MedicalInnovation
-
-
Today, the #CMCiB held a Symposium to celebrate science and biomedical research achievements. Natalia París Sotés, our Global Marketing Director, spoke on "From Medical Device Design to Commercialization," highlighting the core role of R&D at iVascular and the importance of public entities in study definitions and global health strategies centered on patients. Huge thanks to CMCiB for the invitation. #iVascular #CMCiB5years #MedicalDevices #Innovation #PatientFirst
-
-
Elevate your skills in CTO procedures. Our course offers live cases, clinical sessions, and exclusive access to cathlab observations, providing valuable insights and close interaction between participants and leading experts in the field. Do you want to know more? Visit our web ➡️ https://lnkd.in/dqVqeqSu #iVascular #ChronicTotalOcclusions #InterventionalCardiology
-
What’s innovation? It’s creating something unique based on experience and expertise. It’s going further to provide new solutions to meet essential needs. Discover how iCover’s balloon-expandable covered stent ensures excellent navigability and flexibility for precise delivery, even in the most challenging anatomies. iCover, the art of innovation. #iCover #Artofinnovation #coveredstent
-
BARISTA Trial first clinical data of #Restorer BMS include 100% technical success and impressive outcomes: 96.9% primary patency and 98.5% fTLR at 12-month follow-up. Restorer proves efficacy and safety for aortoiliac lesions thanks to its advanced design. BARISTA enrolment has been completed with 200 patients from 14 centers. #iVascular #EndovascularTherapy #MedicalInnovation
-
-
The 9th Annual Multi Level CTO Course 2024 has officially kicked off today in Nice, France! 🌟 Day one has been a fantastic start, filled with insightful sessions in interventional cardiology and coronary chronic occlusions treatment. 📢 Visit us at Booth 9 to learn more about iVascular’s innovative coronary portfolio and don’t miss our upcoming presentations: ✅ Navitian case: Tip-in or not? that’s the question by Dr Ignacio Amat ✅ Naviscore case: When it is more than a simple CTO by Dr Stepahe Carlier We look forward to seeing you there! #MLCTO2024 #InterventionalCardiology #ChronicOcclusions #iVascular #HealthcareInnovation #PatientCare
-
-
Explore a remarkable #ClinicalCase by Dr Alberto Rodríguez. Witness the successful navigation and penetration capacity of Navitian in a long-calcified LAD CTO. Discover more at Navitian's website ➡️ https://lnkd.in/gJphkd-t #iVascular #Navitian #ClinicalCase
-
-
At iVascular, we improve patients' lives with innovation and excellence. #Naviscore, is the result of years of dedication and passion for medical technology. With its hybrid design combining the benefits of scoring and cutting, we are challenging the calcification limits. #rockthecalcium #calcifiedlesion #medicalinnovation #complexcoronarydisease #Cardiovascularresearch
-
-
Attention interventional cardiologists! Time is ticking for the #iCardioGrant 2024 submissions! Grants will be awarded to professionals whose work advances medical knowledge and clinical practice through clinical cases on complex lesions in interventional cardiology, using at least 2 iVascular products. This is your chance to make an impact - submit your case now! ➡️ https://lnkd.in/eAx7p9j2 #iVascular #InterventionalCardiology #MedicalEducation
-